Interferon-α (IFN-α) is currently the most used cytokine in the treatment of cancer. However,
the potential anti-tumour activity of IFN-α is limited by the activation of tumour resistance …

Aims In the metastatic stage, malignant melanoma is resistant to systemic treatment and
carries a poor prognosis. A critical, evidence‐based analysis of standard approaches based …

The purpose of this study was to compare the response rate, overall and 1-year survival in
patients with advanced melanoma treated with a standard therapy, dacarbazine and …

Our results with concurrent biochemotherapy in patients with stage IV melanoma have been
encouraging. Based on these data, we conducted a phase II study to determine the clinical …

The physicochemical properties and antitumor activity of dacarbazine, its analogs, and the
new alkylating agent imidazene are reviewed. It is shown that the activity of dacarbazine is …

This review attempts to summarize the available preclinical and clinical evidence supporting
the inclusion of tamoxifen (TAM) in the treatment of malignant melanoma, in the attempt to …

Malignant melanoma is one of the most worrisome tumors in terms of epidemiology, and
incidence is increasing. The estimated lifetime risk in the United States is 1 in 75 people. As …

Поиск новых лекарственных средств Page 1 Поиск новых лекарственных средств ©
Коллектив авторов, 2010 МАИрадян, НСИрадян, ГМСтепанян, ФГАрсенян, БTГарибджанян …

Das maligne Melanom ist ein hoch maligner Tumor, der von den Melanozyten ausgeht.
Mehr als 90% der Tumoren entwickeln sich primär an der Haut; entsprechend dem …

For many years the mainstay of treatment for metastatic melanoma, chemotherapy is much
less used today. Although a small minority of patients benefit from cytotoxic agents …